Evidence map›Paper›PMID 35341759›Full record

ArticleJournal of immunological methods2022

In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach.

Nimat Ullah, Farha Anwer, Zaara Ishaq, Abubakar Siddique, Majid Ali Shah, Moazur Rahman, Abdur Rahman, Xinrui Mao, TingTing Jiang, Bok Luel Lee and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Overcoming Immune Evasion inACS infectious diseases · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Nimat UllahAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan; Department of Microbiology and Immunology, Indiana University School of Medicine-Northwest, 3400 Broadway, Gary, Indiana 46408, USA.
Farha AnwerAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan.
Zaara IshaqAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan.
Abubakar SiddiqueAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan.
Majid Ali ShahDepartment of Microbiology and Immunology, Indiana University School of Medicine-Northwest, 3400 Broadway, Gary, Indiana 46408, USA.
Moazur RahmanSchool of Biological Sciences, University of the Punjab, Quaid-i-Azam Campus, Lahore 54590, Pakistan.
Abdur RahmanAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan.
Xinrui MaoHost Defense Protein Laboratory, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
TingTing JiangHost Defense Protein Laboratory, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Bok Luel LeeHost Defense Protein Laboratory, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Taeok BaeDepartment of Microbiology and Immunology, Indiana University School of Medicine-Northwest, 3400 Broadway, Gary, Indiana 46408, USA. Electronic address: tbae@iun.edu.
Amjad AliAtta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Sector H-12, Islamabad 44000, Pakistan. Electronic address: amjad.ali@asab.nust.edu.pk.
National University of Sciences and Technology · PKPusan National University · KRIndiana University Northwest · USIndiana University School of MedicineUniversity of the Punjab · PK

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
The mechanism of the beta-lactam resistance in Staphylococcus aureusR01AI143792 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI BAE, TAEOK · 2020 to 2023
$1.6M
NCATS NIH HHS UL1 TR002529NIAID NIH HHS R01 AI143792
6 · The paper itself

Abstract

The vaccine development strategies have evolved from using an entire organism as an immunogen to a single antigen and further towards an epitope. Since an epitope is a relatively tiny and immunologically relevant part of an antigen, it has the potential to stimulate more robust and specific immune responses while causing minimal adverse effects. As a result, the recent focus of vaccine development has been to develop multi-epitope vaccines that can target multiple virulence mechanisms. Accordingly, we designed multi-epitope vaccine candidates B (multi-B-cell epitope immunogen) and CTB-B (an adjuvant - cholera toxin subunit B (CTB) - attached to immunogen B) against S. aureus by employing immunoinformatics approaches. The designed vaccines are composed of B-cell epitope segments (20-mer) of the eight well-characterized S. aureus virulence factors, namely ClfB, FnbpA, Hla, IsdA, IsdB, LukE, SdrD, and SdrE connected in series. The designed vaccines were expressed, purified, and administered to C57BL/6 mice with Freund adjuvant to evaluate the immunogenicity and protective efficacy. The results revealed that the immunized mice showed high IgG titers for the immunogen, and the antibody titers increased significantly following the second immunization. However, the generated antibodies did not protect the mice from infection. The interaction of anti-B antibodies with source virulence factors showed that the generated antibodies have no binding affinity with any of the corresponding virulence factors. Our results demonstrate the limitation of the in silico designed B-cell multi-epitope vaccine and suggest that a protein domain carrying both linear and conformational B-cell epitopes might be a better choice for developing an effective multi-epitope vaccine against S. aureus.

Indexed as

Staphylococcal InfectionsVaccinesAnimalsAntibodiesEpitopes, B-LymphocyteEpitopes, T-LymphocyteMiceMice, Inbred C57BLStaphylococcus aureusVirulence FactorsAntibodiesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVaccinesVirulence FactorsB-cell multi-epitope vaccineImmunoinformaticsIn silico vaccine designMulti-domain approachStaphylococcus aureus

Identifiers

PMID35341759
PMCPMC9040383
OpenAlexW4220952322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.